U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07757191) titled 'DURATION-GC: FLOT Plus Durvalumab and TS-1 Plus Durvalumab for Resectable Gastric Cancer' on July 13.
Brief Summary: To address regional disparity, the investigators propose a tailored perioperative strategy for East Asian patients, combining neoadjuvant FLOT plus durvalumab, followed by adjuvant TS-1 plus durvalumab. This approach seeks to balance efficacy, immunologic synergy, and treatment tolerability, offering a more practical regimen for Eastern populations.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Resectable Gasrtic Cancer
Intervention:
DRUG: Durvalumab, TS-1
This is a single-arm, open-label,...